- Home
- CISS vs PRFX Comparison
CISS vs PRFX Comparison
Compare CISS & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- PRFX
- Stock Information
- Founded
- CISS 2022
- PRFX 2007
- Country
- CISS Greece
- PRFX Israel
- Employees
- CISS N/A
- PRFX 6
- Industry
- CISS Marine Transportation
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- PRFX Health Care
- Exchange
- CISS Nasdaq
- PRFX Nasdaq
- Market Cap
- CISS 2.8M
- PRFX 2.8M
- IPO Year
- CISS N/A
- PRFX 2020
- Fundamental
- Price
- CISS $3.62
- PRFX $1.45
- Analyst Decision
- CISS
- PRFX Hold
- Analyst Count
- CISS 0
- PRFX 1
- Target Price
- CISS N/A
- PRFX N/A
- AVG Volume (30 Days)
- CISS 75.6K
- PRFX 380.5K
- Earning Date
- CISS 08-21-2025
- PRFX 08-14-2025
- Dividend Yield
- CISS N/A
- PRFX N/A
- EPS Growth
- CISS N/A
- PRFX N/A
- EPS
- CISS N/A
- PRFX N/A
- Revenue
- CISS $38,174,754.00
- PRFX N/A
- Revenue This Year
- CISS N/A
- PRFX N/A
- Revenue Next Year
- CISS N/A
- PRFX N/A
- P/E Ratio
- CISS N/A
- PRFX N/A
- Revenue Growth
- CISS N/A
- PRFX N/A
- 52 Week Low
- CISS $2.85
- PRFX $1.25
- 52 Week High
- CISS $23.25
- PRFX $16.63
- Technical
- Relative Strength Index (RSI)
- CISS 56.47
- PRFX 42.12
- Support Level
- CISS $3.30
- PRFX $1.25
- Resistance Level
- CISS $3.99
- PRFX $1.64
- Average True Range (ATR)
- CISS 0.20
- PRFX 0.10
- MACD
- CISS 0.05
- PRFX 0.03
- Stochastic Oscillator
- CISS 50.00
- PRFX 51.28
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.